Developments in the management of anaemia and other complications in adults with chronic kidney disease

After the reading this article, you should be able to:

• Understand how the National Institute for Health and Care Excellence guidance has changed and how this affects the management of chronic kidney disease, including renal anaemia;
• Detail the available treatments for anaemia in patients with chronic kidney disease, including intravenous iron preparations and erythropoiesis-stimulating agents;
• Understand that the emergence of hypoxia-inducible factor prolyl-hydroxylase inhibitors offers an alternative to erythropoiesis-stimulating agents in the management of renal anaemia.